Renal Cell Carcinoma

Sutent Approved for Patients at High Risk of Recurrent RCC

By November 17, 2017

Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.